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Abstract (256 words) 
Background: Owing to hospitalization, reduced functional capacity and consequently, less 
sunlight exposure, sub-optimal vitamin D status (25-hydroxyvitamin D [25(OH)D] <50 
nmol/L) is prevalent among chronic obstructive pulmonary disease (COPD) patients.  
Objective: This study aimed to investigate seasonal changes in vitamin D status and any 
associated changes in fat free mass (FFM), muscle strength and quality of life (QoL) in COPD 
patients.  
Methods: COPD patients living in Northern Ireland (n 51) completed study visits at the end 
of winter (March/April) and at the end of summer (September/October), corresponding to the 
nadir and peak of vitamin D status, respectively. At both time-points, serum concentration of 
25(OH)D was quantified by LC-MS/MS, FFM (kg) was measured using bioelectrical 
impedance and muscle strength (kg) was measured using handgrip dynamometry. QoL was 
assessed using the validated St George’s Respiratory Questionnaire.  
Results: Mean±SD 25(OH)D concentration was significantly higher at the end of summer 
compared to the end of winter [52.5±30.5 nmol/L vs 33.7±28.4 nmol/L, P<0.001]; and 
housebound patients had significantly lower 25(OH)D concentration compared to non-
housebound patients at the end of summer [42.9±4.2 vs 57.2±9.9 nmol/L; P< 0.001]. Muscle 
strength (at both time-points) and QoL (end of summer only) were positively predicted by 
25(OH)D concentration, independent of age, sex and smoking status.  
Conclusion: This study highlights the need for health policies to include a recommendation 
for year-round vitamin D supplementation in housebound COPD patients, and wintertime 
supplementation in non-housebound patients, to maintain optimal 25(OH)D concentrations to 
protect musculoskeletal health. Furthermore, an optimal vitamin D status may have potential 
benefits for QoL in these patients. 
 
Keywords 
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Plain Language Summary (198 words)  
Why was the study done? 
To establish if there was seasonal variation in blood levels of vitamin D in chronic obstructive 
pulmonary disease (COPD) patients. Current patient recommendations suggest 
supplementation during the winter period when vitamin D is at its lowest. This research also 
wanted to establish if there were any links between vitamin D, muscle health and quality of life 
(QoL) in this population.  
What did the researchers do and find? 
Data were collected from a group of COPD patients living in Northern Ireland. They found that 
vitamin D levels were low in the majority of patients. Vitamin D was lower in the winter vs 
summer and in housebound patients vs those who were not housebound. Patients with higher 
vitamin D levels had better muscle strength and better QoL compared to those with lower 
levels. 
What do these results mean? 
These results suggest that there is a need for year-round vitamin D supplementation in COPD 
patients, especially those who do not regularly get outdoors. Ensuring better vitamin D levels 
may be beneficial for muscle strength and QoL in COPD patients. Revised policies and 
education are needed for this patient group to help maintain optimal vitamin D levels. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality 
globally1 with an estimated prevalence of 251 million cases in 2016. COPD is 
characterized by progressive and persistent airflow limitation accompanied by an enhanced 
chronic inflammatory response and is primarily caused by smoking and environmental 
exposure to smoke.2 Increased rates of respiratory infections and inflammatory exacerbations 
in COPD patients result in more frequent hospital stays and more time spent indoors. As a 
result, decreased sunlight exposure, along with a poor dietary intake, glucocorticoid 
medication, ageing, lower vitamin D storage from muscle or fat and renal dysfunction, places 
this patient group at high risk of vitamin D deficiency (25-hydroxyvitamin D [25(OH)D] 
concentrations <25 nmol/L).3-5 One study has reported vitamin D insufficiency (25(OH)D 
<50 nmol/L) in 58% of COPD patients, even during summer months6 with others reporting 
vitamin D insufficiency in up to 79% of moderate to severely affected COPD patients within 
Northern Ireland.7 
 
Vitamin D deficiency, in turn, has been associated with increased rates of exacerbations and 
hospitalization in COPD patients.8,9 Recent meta-analyses have concluded that vitamin D 
deficiency is directly associated with COPD disease severity and vitamin D supplementation 
may prevent exacerbations.10-12 It is purported that this association is mediated through the 
immunomodulatory effects of vitamin D13 by shifting the inflammatory balance from a pro-
inflammatory T-helper cell 1 (Th1) profile towards a more anti-inflammatory T-helper cell 2 
(Th2) profile.14,15 Therefore, achieving optimal vitamin D status might not only help prevent 
comorbidities, such as osteoporosis in COPD patients,16 but may also help prevent respiratory 
infections and exacerbations,9 which have been shown to be predictive of a higher mortality 
risk in this patient group.17 
 
Furthermore, COPD patients present with a severe reduction in physical performance and 
capacity for physical activity, mostly owing to impaired respiratory and muscle functions,18,19 
resulting in a significant deterioration in quality of life (QoL).20 Patients with moderate to 
severe COPD often present with muscle wastage and severe muscle weakness, which can 
manifest as cachexia or sarcopenia, both of which have been associated with increased 
mortality risk and disease severity.21,22 Cachexia in COPD patients is typically diagnosed 
through low body mass index (BMI <18.5 kg/m2) and a low fat free mass index (FFMI),23 
while sarcopenia can be defined as low fat free mass (FFM) with a normal or elevated 
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BMI.24 Although somewhat disputed,25 the vitamin D receptor (VDR) has been detected in 
skeletal muscle cells26 and low vitamin D status has been associated with a higher risk of 
sarcopenia and impaired muscle function in older individuals.27 Nonetheless, the majority of 
studies investigating the potential benefit of optimal vitamin D in COPD patients have focused 
on respiratory outcomes, with a dearth of studies considering its impact on the maintenance 
of muscle mass and function. One recent study reported that vitamin D deficient COPD 
patients had significantly lower hand grip strength and knee flexor muscle strength compared 
to vitamin D sufficient patients,28 while other studies have produced variable results.29-32  
 
Seasonal variations in respiratory infections and exacerbations have been reported in COPD 
patients,33,34 and are comparable to the seasonal variation in vitamin D status.35 Nonetheless, 
seasonality is a poorly considered aspect of most vitamin D studies in COPD populations. 
Therefore, the primary aim of this study was to investigate the seasonality of vitamin D status 
in COPD patients. Secondary aims were to investigate if muscle strength and QoL were 
predicted by vitamin D status.
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Methods  
Participants 
Individuals with diagnosed stable COPD were recruited from the Belfast and Western Health 
and Social Care Trusts within Northern Ireland (53-55°N), at community dietician home visits 
and pulmonary rehabilitation clinics. Exclusion criteria were: <18 yr old, pregnancy or having 
a diagnosis of lung cancer. Patients were given a verbal outline of the study by clinicians, 
along with a short written information sheet. Following this visit, those patients who expressed 
interest in the study provided consent for their details to be passed onto a researcher. Interested 
patients were then contacted via telephone and/or visited by a researcher at their home, where 
they received a full verbal explanation, full participant information sheet and given at least 48 
hours to consider participating in the study. Full written informed consent was obtained from 
those who participated. This study was approved by The Office for Research Ethics 
Committee Northern Ireland (ORECNI; 12/NI/0183) and was conducted according to the 
Declaration of Helsinki. 
 
Study design  
A researcher visited patients twice at their home over the course of the study: the first at the 
end of winter (March/April) and the second, at the end of summer (September/October), 
corresponding to the nadir and peak of vitamin D status, respectively. This study took place 
over 2 years: 39 patients completed the study between March and October 2013 and the 
remaining 12 patients completed the study between March and October 2014. Using data from 
a previous study investigating seasonal differences in vitamin D status in older adults in this 
population36, it was calculated that to achieve a power of 80% and a level of significance of 
5% (one sided), and allowing for a 40% drop out rate, a minimum of 44 patients should be 
recruited to see a significant seasonal difference in 25(OH)D concentrations. 
 
Questionnaires  
Health and lifestyle questionnaires were completed at both time-points for information on 
smoking status, sun exposure habits and medical history. Patients self-defined themselves as 
being house-bound or non-housebound according to whether they spent the majority of 
their waking hours at home or not. This definition was confirmed by the researcher using 
responses from the sun exposure habits section of the health and lifestyle questionnaire 
which estimated time spent outdoors during April-September. Daily number of cigarettes 
and number of years smoking were used to calculate ‘smoking pack years’ as: 
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Smoking pack years: (number of cigarettes daily X years smoking) / 20 
A validated St. George’s Respiratory Questionnaire (SGRQ) was also completed at both time- 
points to assess QoL.37 SGRQ scores were out of 100, with 100% indicating the most lifestyle 
limitations or poorest QoL. 
 
Anthropometry and muscle strength 
Height (m) was measured at the first time-point using a portable stadiometer (Seca, Hamburg, 
Germany). Weight (kg), body mass index (BMI, kg/m2) and FFM ( kg) were measured at 
both time-points by bioelectrical impedance analysis, using portable Tanita scales (Tanita 
Corporation, Tokyo, Japan). FFMI (kg/m2) was calculated by correcting FFM for height 
(FFM (kg)/height (m2)). Muscle strength (kg) was measured at both time-points using a 
Smedley hand-grip dynamometer (Stoelting, Illinois, USA). Three repetitions of a maximal 
isometric contraction were performed on the non-dominant arm, with 30 seconds rest between 
repetitions. Average of the three repetitions was calculated as overall grip strength and patients 
who were unable to complete all three repetitions had the average of two repetitions recorded. 
 
Biochemical Analysis 
Non-fasting 10ml blood samples were collected by venepuncture into blood collection tubes 
by a fully trained phlebotomist at both time-points and were processed to serum/plasma within 
4 hours of collection. Aliquots were stored at -80˚C until required for batch analysis at the end 
of the study. Total serum 25(OH)D (sum of 25(OH)D2 + 25(OH)D3) concentrations were 
quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS, API 4000, 
AB SCIEX, Foster City, CA, USA) following sample preparation according to kit 
manufacturer guidelines from Chromsystems Instruments & Chemicals GmbH, Munich, 
Germany (MassChrom® 25-OH-Vitamin D3/D2), at St James’s Hospital, Dublin. This 
laboratory participates in the Vitamin D External Quality Assessment Scheme (DEQAS). 
Vitamin D insufficiency is classified as 25(OH)D concentrations <50 nmol/L. Plasma intact 
parathyroid hormone (PTH) concentrations were measured using a manual enzyme-linked 
immunoassay at Ulster University, with a commercially available kit (MD Bioproducts, 
Division of Biosciences, Inc, St Paul, MN, USA). All samples were measured in duplicate and 
the mean of the two replicates calculated, with precision ensured via bi-level quality controls. 
Serum calcium (Ca+), creatinine, albumin and high sensitivity C-reactive protein (CRP) 
concentrations were measured using an ILab™ 600 Chemistry Systems auto-analyzer. The 
normal reference range for CRP was <10mg/L. Albumin-adjusted Ca+ concentration was 
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calculated using serum albumin and calcium concentrations: 
Serum calcium (mmol/L) + 0.8 X (40-albumin (g/L)) 
Renal function was assessed by calculating estimated glomerular filtration rate (eGFR, 
mL/min/1.73m2), using the age and sex-specific Modification of Diet in Renal Disease 
(MDRD) formula38: 
186 X (serum Creatinine X 0.0113) – 1.154 x (age) – 0.203 X (0.742 if female) 
 
Statistical Analysis 
Statistical analyses were carried out using SPSS® for Windows™ Version 22.0 (IBM SPSS® 
Statistics, Armonk, NY). All variables were tested for normality using Kolmogorov-Smirnov 
and those data, which were not normally distributed, were log transformed to achieve near 
normal distribution. Data are presented as mean±SD, unless otherwise stated. Differences in 
means between the end of winter and end of summer were assessed for vitamin D, muscle and 
SGRQ outcome variables, using paired t tests. Spearman’s correlation analysis was used to 
assess correlations between serum 25(OH)D and CRP concentration, muscle outcomes and 
SGRQ scores at each time-point. Stepwise linear regressions were performed to investigate 
serum 25(OH)D concentration as a predictor of muscular outcomes [FFM (kg), FFMI (kg/m2), 
muscle strength (kg)] and SGRQ scores at both time-points. Linear regression models included 
age, sex and smoking status (active, previous or never) as covariates. FFM (kg) was an 
additional covariate in muscle strength models only. A P value <0.05 was considered 
statistically significant throughout. 
 Page 9 of 24 
Results 
A total of 51 COPD patients (n 28 males, n 23 females), with a mean±SD age of 68.7±7.2 
years, completed both seasonal time-points of the study: the end of winter and end of summer. 
Table 1 represents the patient characteristics, anthropometry, muscle mass, muscle strength 
and biochemical parameters at each seasonal time-point. There were no significant 
differences in any of these variables between the two years of recruitment or between the 
two Health and Social Care Trust areas (data not shown). At the end of winter, 31%, 67% and 
2% actively, previously and never smoked, respectively; whereas, at the end of summer, the 
proportion of active smokers significantly increased to 41%. There were no significant 
differences in body weight (kg), BMI (kg/m2), FFM (absolute [kg] or %), FFMI ( k g / m 2 ) or 
muscle strength between the two seasonal time-points. Mean values for BMI at both time-
points were within the overweight BMI category (25.0-29.9 kg/m2). 
 
At the end of summer 25(OH)D concentrations were significantly higher compared to the end 
of winter (52.5±30.5 vs 33.7±28.4 nmol/L). A total of 75% and 47% of patients were classified 
as vitamin D deficient/insufficient (25(OH)D <50 nmol/L) at the end of winter and summer, 
respectively. Non-housebound (n 35) patients had significantly higher mean±SD 25(OH)D 
concentration compared to housebound patients (n 16) at the end of summer (57.2±9.9 vs 
42.9±4.2 nmol/L, P=0.029), but there was no significant difference at the end of winter (Figure 
1). Nonetheless, both housebound and non-housebound patients had a significantly higher 
25(OH)D concentration at the end of summer compared to the end of winter (housebound: 
42.9 vs 31.1 nmol/L, P=0.006 and non-housebound: 57.2 vs 35.2 nmol/L, P<0.001). 
 
Whilst there were statistically significant seasonal differences in albumin- adjusted Ca+ and 
creatinine concentrations and eGFR, these differences were not considered clinically 
significant and reflect the associated seasonal changes in 25(OH)D concentrations. There was 
no significant seasonal variation in PTH or CRP concentration and no significant difference in 
QoL (SGRQ scores) between the two seasonal time-points.  
 
Absolute FFM (kg), FFMI and CRP concentrations were not significantly correlated with 
serum 25(OH)D concentration at any time-point (Table 2). Muscle strength was significantly 
positively, and SGRQ score, negatively associated with serum 25(OH)D concentration at 
the end of summer, but not at the end of winter. Stepwise linear regression analyses (Table 
3) showed that serum 25(OH)D concentration was not a significant predictor of absolute 
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FFM (kg), or FFMI at either time-point but was a significant positive predictor of muscle 
strength at both time-points. Higher serum 25(OH)D concentration significantly predicted a 
better QoL (lower SGRQ score) at the end of summer, but not the end of winter, after 
adjusting for age, sex and smoking status. Additional analyses presented in Table 4, show 
that at the end of summer only, vitamin D insufficient (25(OH)D <50 nmol/L) patients had 
significantly lower muscle strength and QoL (higher SGRQ score), compared to vitamin D 
sufficient patients (≥50 nmol/L) and are significantly more likely to be housebound. 
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Discussion 
This is the first prospective study to report seasonal variability in vitamin D status in COPD 
patients within Northern Ireland, as well as significantly lower vitamin D status in COPD 
patients who are housebound compared to those who are non-housebound. In this patient 
group, serum 25(OH)D concentration also positively predicted muscle strength at both the end 
of winter and end of summer, and QoL (according to SGRQ scores) at the end of summer. 
Moreover, those patients who did not achieve a sufficient vitamin D status at the end of 
summer, when vitamin D status is expected to be at its highest, had significantly lower muscle 
strength and a lower QoL compared to those whose 25(OH)D concentration reached ≥50 
nmol/L. 
 
In this COPD patient cohort, the seasonal variation in 25(OH)D concentrations observed 
mirror those recently reported in the general healthy older Irish population in The Irish 
Longitudinal Study on Ageing (TILDA),35 albeit at concentrations approximately 10-20 
nmol/L lower than the healthy cohort. The current findings are comparable to those from other 
European COPD cohorts.4,32 In contrast, a cross-sectional observation study of COPD patients 
in Northern Ireland reported no difference in vitamin D status across season of sampling. The 
study, however, found a higher year-round prevalence of vitamin D insufficiency (79% 
<50nmol/L);7 results comparable to the proportion of COPD patients in the current study with 
insufficient vitamin D status at the end of winter (75%). 
 
The current study has shown that non-housebound COPD patients have a significantly higher 
vitamin D status, compared to housebound patients at the end of summer, but not at the end 
of winter. Vitamin D deficiency/insufficiency is prevalent in three quarters of the overall 
cohort at the end of winter, but remains prevalent in housebound patients, even at the end of 
summer, when vitamin D is expected to be highest, reflecting the lack of cutaneous vitamin D 
synthesis at this latitude (53-55°N) during these months (October-March).39 Similar findings 
have been reported in other housebound and institutionalized populations with severely 
reduced opportunity for sunlight exposure, such as nursing home patients40 and hospitalized 
COPD patients.5 These findings highlight a policy requirement for vitamin D supplementation 
to optimize vitamin D status throughout the year in housebound COPD patients and during 
winter months in non-housebound patients. 
 
Although there was a significant seasonal variation in 25(OH)D concentration, this was not 
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reflected by seasonal variations in body composition, according to BMI, FFM or FFMI. In 
addition, FFM and FFMI were not correlated with 25(OH)D concentration at either seasonal 
time-point. Mean BMI at both seasonal time-points was within the overweight category (BMI 
25.0-29.9 kg/m2), which has been associated with poor vitamin D status in some studies,41,42 
including COPD populations.43 Nonetheless, BMI cannot distinguish between fat mass (FM) 
and FFM, which is particularly important in COPD patients, who are at risk of sarcopenia22 or 
sarcopenic obesity (normal BMI but with low FFM and increased FM).44 Despite no 
significant associations between body composition and 25(OH)D concentration it is 
encouraging that in a population with a chronic and progressive disease, such as COPD, there 
is no significant deterioration in FFM over approximately 6 months. 
 
Compromised muscle strength and physical performance is a common manifestation of 
vitamin D deficiency in generally healthy older individuals.45,46 The current study has shown 
that serum 25(OH)D concentration is a positive predictor of muscle strength (as measured by 
grip strength) at both the end of winter and end of summer, and this association was stronger 
at the end of summer, when vitamin D status was higher. Indeed, in the current study, muscle 
strength was also approximately 40% higher in patients who reached vitamin D sufficiency at 
the end of summer compared to those who remained insufficient/deficient, confirming 
previous observations by others.28 Furthermore, those patients who reached vitamin D 
sufficiency at the end of summer were also more likely to be non-housebound patients, 
reflecting the major source of vitamin D being sun exposure in this cohort. In addition, it 
is possible, although speculative that those patients who are not housebound may be 
partaking in more outdoor activities, albeit physical activity was not assessed as part of 
this study. Of interest, previous studies have not replicated this association between 
25(OH)D concentration and muscle outcomes in COPD patients who are vitamin D replete 
(25(OH)D ≥50 nmol/L),31 unlike those reported in the current study. Therefore, it is possible 
that an effect of vitamin D on muscle in COPD patients may only be observed in those who 
are vitamin D deficient/insufficient at baseline or in patients with particular genetic variations 
in genes associated with vitamin D metabolism such as FokI and Bsml VDR polymorphisms 
which have been shown to influence associations between vitamin D and its functions.47 Both 
of these factors should be considered in future randomized-controlled trials in this group.  
 
Genomic and non-genomic mechanisms have been proposed to explain the beneficial effect of 
vitamin D on muscle and the suggested genomic mechanism, mediated via the VDR, results 
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in proliferation of muscle proteins, predominantly type II muscle fibre proteins.48 This does 
not seem a plausible mechanism to explain the associations in this study, as we might also 
expect an increase in FFM owing to increased type II muscle fibres. Rather, the faster 
intracellular, non-genomic mechanism seems a more appropriate explanation. This mechanism 
suggests that the active form of vitamin D, 1,25 dihydroxyvitamin D (1,25(OH)2D3) acts upon 
Ca+ channels on the cell membrane, allowing for an increased flux of intracellular Ca+, 
improving muscle function and contractility.49 Further investigation is required to determine 
the exact mechanisms by which vitamin D influences muscle strength in normal populations, 
as well as those with compromised muscle function, such as those diagnosed with COPD. 
 
Previous literature has suggested the importance o f  optimal vitamin D status on respiratory 
function and the frequency of exacerbations in COPD patients,8,12, 33,50-54 which may also 
influence winter time mortality rates.34 Although the current study cannot provide information 
on respiratory function, disease severity or exacerbation frequency, we do report data on CRP 
concentrations similar to other stable COPD cohorts55 and which may be a possible 
mediating factor between vitamin D and respiratory function.52 In the current study, CRP 
did not differ significantly between the seasons, and was not correlated with serum 25(OH)D 
concentration at either time-point, a finding which confirms the findings of others.52 While 
higher concentrations of CRP have been associated with impaired lung function, the role of 
CRP in the etiology of COPD and respiratory function remains poorly understood.56,57 Further 
research is also warranted to elucidate the relationship between vitamin D and immune-
respiratory function in COPD. 
 
Disease severity and exacerbations have been shown to considerably impact upon the QoL in 
COPD patients.58,59 The current study has shown for the first time that higher serum 25(OH)D 
concentration are predictive of lower SGRQ scores and thus a better QoL, independent of age, 
sex and smoking status in COPD patients. These results are in contrast to a Korean COPD 
population where no significant association was found between vitamin D 
status and QoL at similar 25(OH)D concentration.60 It is noteworthy, however, that 
in the current study, QoL score was assessed by a subjective self-reported questionnaire and it 
is possible that higher vitamin D status was a result of a better QoL as patients who reported 
less lifestyle limitations were more likely to spend time outdoors. This finding might also 
explain why the association was evident at the end of summer, when cutaneous vitamin D 
synthesis was possible from sunlight exposure, but not at the end of winter.  
 Page 14 of 24 
 
Although this is an observational study, and the findings might not indicate cause and 
effect, it analyzes the prospective association between vitamin D status, muscle function, CRP 
and QoL in a group of COPD patients, with a specific focus on seasonality. Another strength 
is that serum 25(OH)D concentrations were quantified using the gold standard LC-MS/MS 
method by a laboratory participating in the Vitamin D External Quality Assurance Scheme 
(DEQAS). One limitation of the current study is the absence of data on respiratory function, 
disease severity and exacerbations, which may have been significant covariates in the current 
analyzes. Such clinical markers should be routinely measured and recorded for all 
patients and this monitoring should be reflected in COPD clinical management 
guidelines and policy. Dietary vitamin D intake, including supplementation, was also not 
assessed in this study and may be useful for clinicians to help recommend the best strategy to 
improve intake and increase status as necessary. 
 
In conclusion, to t h e  a u t h o r s ’  knowledge, this is the first p r o s p e c t i v e  study to 
demonstrate the seasonality of vitamin D status in COPD patients and importantly noting 
these differences between housebound and non-housebound patients. Moreover, specifically 
at the end of summer, housebound COPD patients had significantly lower vitamin D status 
compared to n o n - housebound patients, and worryingly, a greater proportion remained 
deficient/insufficient at this time-point when vitamin D status should have been at its highest. 
This finding demonstrates the efficacy of cutaneous vitamin D synthesis from sunlight 
exposure and highlights the importance of optimizing QoL in this at-risk patient group to 
facilitate time spent outdoors regularly. Currently vitamin D is not considered as part of the 
recommended management of COPD by NICE guidelines in the UK, but the recently revised 
reference nutrient intake of 10µg/d (400 IU) for the general population should apply to this 
population and assumes minimal sunshine exposure.61 Findings from the current study may 
directly impact on policy as they suggest a requirement for year-round vitamin D 
supplementation particularly for housebound COPD patients and during winter for non-
housebound patients, as a relatively inexpensive and effective means of optimizing vitamin D 
status and not least maintaining 25(OH)D concentrations to protect musculoskeletal health. The 
potential positive influence of optimal vitamin D on muscle strength and QoL, as reported in 
the current study, may in turn lead to improved exercise tolerance, physical function and 
slower deterioration of respiratory function in COPD patients. Such results should also help 
inform healthcare and professional and patient education programmes and policy on vitamin 
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D supplementation in this population group with the ultimate aim to ensure adequate vitamin 
D status in patients with COPD. 
 
Acknowledgements 
The authors wish to thank all patients who participated in the study and the respiratory nurses 
who assisted with sample collection. The study was jointly funded by the Western Health and 
Social Care Trust Research Office and the Biomedical Sciences Research Institute, Ulster 
University. The funding sources had no input into the study design, collection, analysis or 
interpretation of the data and/or production of the manuscript. 
 Page 16 of 24 
Table 1 Characteristics of COPD patients at the end of winter and end of summer 
 End of winter End of summer P-valuea 
n (% male) 51 (55)   
Age (years) 68.7 ± 7.2   
Height (cm) 162.4 ± 9.6   
Weight (kg) 73.6 ± 21.8 73.0 ± 21.2 0.195 
BMI (kg/m2) 27.3 ± 7.8 27.2 ± 7.5 0.399 
FFM (kg) 50.2 ± 9.6 50.1 ± 9.5 0.883 
FFM (%) 69.3 ± 11.8 70.4 ± 12.6 0.506 
FFMI (kg/m2) 18.57 ± 2.64 18.54 ± 2.69 0.849 
Muscle strength (kg) 23.2 ± 10.9 23.9 ± 11.3 0.963 
25(OH)D (nmol/L) 33.7 ± 28.4 52.5 ± 30.5 <0.001 
Adjusted Ca+ (mmol/L)c 2.17 ± 0.17 2.32 ± 0.07 <0.001 
PTH (pg/mL) 70.1 ± 38.1 64.4 ± 40.3 0.059 
Creatinine (μmol/L) 84.9 ± 21.0 93.6 ± 20.7 <0.001 
eGFR (mL/min/1.73m2) 76.1 ± 19.0 67.0 ± 11.9 <0.001 
CRP (mg/L)  8.35 ± 10.29 8.25 ± 9.06 0.792 
Smoking status    
Current n (%) 16 (31) 21 (41)  
Previous n (%) 34 (67) 29 (57)  
Never n (%) 1 (2) 1 (2) <0.001b 
Smoking pack years 44.6 ± 39.3 44.8 ± 39.4 0.030 
SGRQ score (%) 60.8 ± 19.8 61.8 ± 21.2 0.948 
Notes: Data presented as mean ± standard deviation, unless otherwise stated. 
aPaired samples t test (conducted on log transformed data) or bChi square test to assess 
significant differences between the end of winter and end of summer. cCalcium adjusted for 
albumin. 
Abbreviations: BMI, body mass index; CRP, C-reactive protein; eGFR, estimated glomerular 
filtration rate; FFM, fat free mass; FFMI, fat free mass index; PTH, parathyroid hormone; 
SGRQ, St George’s Respiratory Questionnaire; 25(OH)D, 25-hydroxyvitamin D.  
17 
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Figure 1 Mean (S.E. bars) 25(OH)D concentration for housebound (n 16) and non-housebound (n 35) COPD patients at the end of winter and end 
of summer 
Notes: Differences in 25(OH)D concentration between housebound and non-housebound patients, within each season tested using independent 
samples t test and differences in 25(OH)D concentration for each group between each season tested using paired samples t test (conducted on log 
transformed data. Dashed lines represent the level of vitamin D sufficiency (25(OH)D ≥50 nmol/L) and deficiency (25(OH)D < 25nmol/L). 
Abbreviations: COPD, chronic obstructive pulmonary disease; 25(OH)D, 25-hydroxyvitamin D.
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Table 2 Correlation analysis between serum 25(OH)D concentration and muscle outcomes, 
quality of life and CRP concentration of COPD patients at the end of winter and end of summer 
 End of winter  End of summer 
 r P-value  r P-value 
FFM (kg) 0.089 0.588  0.270 0.092 
FFMI (kg/m2) -0.028 0.866  0.171 0.297 
Muscle strength (kg) 0.191 0.243  0.344 0.024 
SGRQ score (%) -0.058 0.712  -0.323 0.028 
CRP (mg/L) -0.223 0.141  -0.149 0.327 
Notes: r, Spearman’s rho correlation coefficient. 
Abbreviations: CRP, C-reactive protein; FFM, fat free mass; FFMI, fat free mass index; 
SGRQ, St. George’s Respiratory Questionnaire; 25(OH)D, 25-hydroxyvitamin D. 
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Table 3 Stepwise linear regression models to investigate 25(OH)D concentration as a predictor of FFM, muscle strength and quality of 
life in COPD patients at the end of winter and at the end of summer 
 End of winter  End of summer 
 R2 β S.E. P-value  R2 β S.E. P-value 
FFM (kg)          
   1 0.008 0.089 0.041 0.588  0.073 0.270 0.036 0.092 
   2 0.554 0.034 0.028 0.760  0.485 0.169 0.028 0.166 
   3 0.554 0.009 0.035 0.761  0.486 0.169 0.028 0.171 
   4 0.652 0.120 0.026 0.261  0.504 0.179 0.028 0.147 
FFMI (kg/m2)          
   1 0.001 -0.028 0.028 0.866  0.029 0.171 0.026 0.297 
   2 0.168 -0.066 0.026 0.662  0.116 0.123 0.026 0.444 
   3  0.204 -0.068 0.026 0.653  0.119 0.123 0.026 0.448 
   4 0.351 0.035 0.025 0.804  0.158 0.140 0.026 0.388 
Muscle strength (kg)          
   1 0.037 0.191 0.109 0.243  0.118 0.344 0.110 0.024 
   2 0.325 0.170 0.092 0.222  0.501 0.243 0.085 0.038 
   3 0.434 0.179 0.086 0.168  0.530 0.258 0.081 0.021 
   4 0.490 0.227 0.084 0.079  0.582 0.254 0.080 0.022 
   5 0.553 0.285 0.082 0.041  0.610 0.271 0.082 0.022 
SGRQ (%)          
   1 0.003 -0.058 0.072 0.712  0.105 -0.323 0.079 0.028 
   2 0.014 -0.069 0.073 0.663  0.112 -0.306 0.081 0.042 
   3 0.045 -0.054 0.073 0.737  0.123 -0.303 0.082 0.046 
   4 0.039 -0.064 0.076 0.698  0.132 -0.316 0.083 0.042 
Notes: Statistical models (1) unadjusted; (2) adjusted for sex; (3) adjusted for sex and age; (4) adjusted for sex, age and smoking status and (5) 
adjusted for age, sex, smoking status and FFMI. R2, coefficient of determination; β, standardized beta regression coefficient. 
Abbreviations: FFM, fat free mass; FFMI, fat free mass index; SGRQ, St George’s Respiratory Questionnaire; 25(OH)D, 25-hydroxyvitamin D 
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Table 4 Muscle function outcomes according to vitamin D insufficiency (25(OH)D <50nmol/L) and sufficiency (≥50nmol/L) in COPD 
patients at the end of winter and at the end of summer 
 End of winter End of summer 
 Insufficient 
(<50 nmol/L) 
Sufficient 
(≥50 nmol/L) 
P-value Insufficient 
(<50 nmol/L) 
Sufficient 
(≥50 nmol/L) 
P-value 
Housebound (%) 36.8 18.2 0.425 52.2 15.4 0.015 
Muscle strength (kg) 24.4 ± 11.0 24.3 ± 11.5 0.559 19.0 ± 9.5 27.6 ± 11.6 0.016 
SGRQ (%) 62.7 ± 18.4 51.8 ± 24.2 0.189 71.3 ± 9.4 54.5 ± 5.5 0.014 
Notes: Chi2 crosstabs test to assess associations between patients who are housebound and level of vitamin D sufficiency. Independent samples t 
test to assess significant differences in muscle strength and SGRQ between vitamin D insufficient and vitamin D sufficient individuals 
Abbreviations: SGRQ, St George’s Respiratory Questionnaire; 25(OH)D, 25-hydroxyvitamin D 
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